Evert K, Stiegler C, Schäfer C, Palme K, Horndasch E, Reitinger S, Rau B M, Dietmaier W, Evert M
Institut für Pathologie, Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
Medizinische Klinik II, Kliniken des Landkreises Neumarkt in der Oberpfalz, Neumarkt, Deutschland.
Pathologe. 2019 Sep;40(5):540-545. doi: 10.1007/s00292-018-0546-3.
Adenosquamous carcinoma (ASqC) is an exceedingly rare subtype of colorectal cancer without any known special guidelines for treatment. The biological behaviour and molecular background are widely unknown, although a few case studies report a worse prognosis compared to ordinary colorectal adenocarcinoma. We herein report for the first time the successful immune checkpoint inhibitor therapy in a 40-year-old patient suffering from metastasized right-sided colonic ASqC with unique molecular features, after having previously progressed under standard chemotherapy.
腺鳞癌(ASqC)是一种极其罕见的结直肠癌亚型,目前尚无已知的特殊治疗指南。尽管一些病例研究报告显示,与普通结直肠腺癌相比,其预后较差,但其生物学行为和分子背景仍广为人知。我们在此首次报告了一名40岁患有转移性右侧结肠ASqC且具有独特分子特征的患者,在先前接受标准化疗进展后,成功接受免疫检查点抑制剂治疗的病例。